A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers-Reference-Cited by-同舟云学术

A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers

Published:2018-05-24 Issue:4 Volume:16 Page:467-477
ISSN:1476-5810
Container-title:Veterinary and Comparative Oncology
language:en
Short-container-title:Vet Comp Oncol

Author:

Abma E.¹²^ORCID,De Spiegelaere W.³,Vanderperren K.⁴,Stock E.⁴,Van Brantegem L.⁵,Cornelis I.¹^ORCID,Daminet S.¹,Ni Y.⁶,Vynck M.⁷,Verstraete G.⁸,Smets P.¹,de Rooster H.¹²

Affiliation:

1. Small Animal Department, Faculty of Veterinary Medicine; Ghent University; Ghent Belgium

2. Cancer Research Institute Ghent (CRIG), Medical Research Building; University Hospital Ghent; Ghent Belgium

3. Department of Morphology, Faculty of Veterinary Medicine; Ghent University; Ghent Belgium

4. Department of Medical Imaging and Orthopedics of Small Animals, Faculty of Veterinary Medicine; University of Ghent; Ghent Belgium

5. Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine; Ghent University; Ghent Belgium

6. Theragnostic Lab, Department of Imaging and Pathology; KU Leuven; Leuven Belgium

7. Department of Data Analysis and Mathematical Modeling, Faculty of Bioscience Engineering; Ghent University; Ghent Belgium

8. Laboratory of Pharmaceutical Technology; Ghent University; Ghent Belgium

Funder

Agency for Innovation & Entrepreneurship

Belgian Animal Cancer Foundation

Publisher

Wiley

Subject

General Veterinary

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/vco.12402/fullpdf

Reference54 articles.

1. The tumour microcirculation as a target in cancer therapy: a clearer perspective;Denekamp;Eur J Clin Invest,1999

2. Vascular targeting agents as cancer therapeutics;Thorpe;Clin Cancer Res,2004

3. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents;Siemann;Cancer Treat Rev,2011

4. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature;Dark;Cancer Res,1997

5. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate;Chaplin;Anticancer Res,1999

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti‐tumor and cardiotoxic effects of microtubule polymerization inhibitors: The mechanisms and management strategies;Journal of Applied Toxicology;2023-07-26

2. Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity;Biomedicine & Pharmacotherapy;2023-04

3. Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats;Journal of Toxicologic Pathology;2023

4. Assessment of Cardiotoxicity after a Single Dose of Combretastatin A4-Phosphate in Dogs Using Two-Dimensional Speckle-Tracking Echocardiography;Animals;2022-11-02

5. B-Mode and Contrast-Enhanced Ultrasonography Aspects of Benign and Malignant Superficial Neoplasms in Dogs: A Preliminary Study;Animals;2022-10-14